The primary objective of the study is to assess adverse events (AEs) and serious adverse events (SAEs) in kidney transplant recipients previously treated with REGN5459 or REGN5458 in the R5459-RT-1944 study.
The secondary objectives of the study are to evaluate each of the following in kidney transplant recipients previously treated with REGN5459 or REGN5458:
- Rates and classification of antibody-mediated and T-cell-mediated kidney allograft rejection
- Graft survival
- Allograft function
- Delayed allograft function
- Anti-human leukocyte antigen (HLA) alloantibody levels and calculated panel-reactive antibody (cPRA)
- Emergence of de novo donor-specific antibodies
- Circulating immunoglobulin (Ig) classes (isotypes)
- Pharmacokinetics (PK) of REGN5459 or REGN5458
A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) Who Receive A Kidney Transplant
